Chemotherapy of Plasma-Cell Myeloma

Publisher Website
Google Scholar
Abstract
To the Editor: I would like to comment on the article in the October 4 issue, in which Dr. Bergsagel and his co-workers discussed the lack of benefit of multiple alkylating-agent combination therapy over melphalan and prednisone in myeloma; I am especially concerned with their interpretation of the M-2 results.1 There are important differences between their program and the M-2 program that may have affected their results and, furthermore, may demonstrate the reported benefits of the M-2 protocol.There was no patient selection in our protocol, as suggested by Bergsagel et al. ("patients destined to die early were not entered"). . . .